BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

被引：0
|
作者：
Song, Erwei
Yao, Herui
Sun, Meili
Zong, Hong
Lin, Rongbo
Zou, Wen
Ding, Muran
Yu, Jing
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin
Zhu, Yi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-04-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-04-03
引用
收藏
页数：3
相关论文
共 50 条
  • [1] BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
    Song, E.
    Yao, H.
    Wang, Y.
    Zeng, Y.
    Sun, M. L.
    Zong, H.
    Lin, R.
    Wen, Z.
    Ding, R. M.
    Yu, J.
    Xiao, S.
    Wang, H.
    Zhu, H.
    Olivo, M. S.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S478 - S479
  • [2] Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
    Pegram, M.
    Hamilton, E.
    Tan, A. R.
    Storniolo, A. M.
    Elgeioushi, N.
    Marshall, S.
    Abdullah, S.
    Patel, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
    Zhang, Jian
    Du, Yiqun
    Meng, Yanchun
    Liu, Xiaojun
    Mu, Yuxin
    Liu, Yunpeng
    Shi, Yehui
    Wang, Jufeng
    Zang, Aimin
    Gu, Shanzhi
    Liu, Tianshu
    Zhou, Huan
    Guo, Hongqian
    Xiang, Silong
    Zhang, Xialu
    Wu, Suqiong
    Qi, Huanhuan
    Li, Mengke
    Hu, Xichun
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [4] A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer
    Hu, Xichun
    Zhang, Jian
    Ji, Dongmei
    Xia, Gang
    Ji, Yanping
    Xiong, Gaozhun
    Liang, Xuejun
    CANCER RESEARCH, 2020, 80 (04)
  • [5] First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
    Park, Yeon Hee
    Ahn, Hee Kyung
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Kim, Seol-Hee
    Lee, Sunbae
    Chung, Hye-Shin
    Park, Soon Jae
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
    Pegram, Mark D.
    Hamilton, Erika P.
    Tan, Antoinette R.
    Storniolo, Anna Maria
    Balic, Kemal
    Rosenbaum, Anton, I
    Liang, Meina
    He, Peng
    Marshall, Shannon
    Scheuber, Anita
    Das, Mayukh
    Patel, Manish R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1442 - 1453
  • [7] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [8] A phase lb, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Burris, Howard A.
    Barve, Minal A.
    Hamilton, Erika Paige
    Bardia, Aditya
    Soliman, Hatem Hussein
    Jarlenski, Donna
    Mosher, Rebecca
    Bergstrom, Donald Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study
    Zhang, Jian
    Ji, Dongmei
    Cai, Li
    Yao, Herui
    Yan, Min
    Wang, Xiaojia
    Shen, Weina
    Du, Yiqun
    Pang, Hui
    Lai, Xiuping
    Zeng, Huiai
    Huang, Jian
    Sun, Yan
    Peng, Xinxin
    Xu, Junfang
    Yang, Jing
    Yang, Fei
    Xu, Ting
    Hu, Xichun
    CANCER RESEARCH, 2022, 82 (04)
  • [10] First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
    Zhang, Jian
    Ji, Dongmei
    Cai, Li
    Yao, Herui
    Yan, Min
    Wang, Xiaojia
    Shen, Weina
    Du, Yiqun
    Pang, Hui
    Lai, Xiuping
    Zeng, Huiai
    Huang, Jian
    Sun, Yan
    Peng, Xinxin
    Xu, Junfang
    Yang, Jing
    Yang, Fei
    Xu, Ting
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 618 - 628
12345